The Myriad Breast Cancer Risk Assessment Program

Identify high-risk patients sooner and improve preventive care

This program contains a suite of breast cancer risk assessment resources, several of which were recently featured in the February 2025 issue of Obstetrics & Gynecology (The Green Journal), to help providers meet hereditary cancer risk assessment guidelines and increase the number of guideline-eligible patients who go on to complete a test.

The suite of tools included in this program are responsible for a more than 2x increase in the percentage of patients who go on to complete hereditary cancer testing1

In a study of five U.S. community OB/GYN practices, clinicians were provided with Myriad Breast Cancer Risk Assessment tools and trained to use them. After eight weeks, results showed the online screening and patient education tools to be extremely effective. 

Simply by using the full suite of tools offered, these five clinics more than doubled the percentage of patients who went on to complete hereditary cancer testing.1

2x increase in testing completion rate

16%

completed the test prior to intervention*

right arrow icon

34%

completed the test post intervention*

*Of those who met guidelines and were offered testing

2x increase in testing completion rate

16%

completed the test prior to intervention*

right arrow icon

34%

completed the test post intervention*

*Of those who met guidelines and were offered testing

1 in 4 patients meet the criteria for hereditary cancer testing2

Ensure your patients’ hereditary cancer risk factors don’t go undetected. Identify high-risk patients for potentially life-saving screenings with the help of the Myriad Breast Cancer Risk Assessment resources.

A suite of risk assessment tools that supports and simplifies hereditary cancer risk management

Hereditary cancer risk assessment is recommended by the American College of Obstetricians and Gynecologists (ACOG) as a standard part of women’s health care.2

It’s proven to enhance early detection and diagnosis, but there’s often a lack of understanding of genetic testing among patients — and a lack of support for busy clinicians.3

The Myriad Breast Cancer Risk Assessment Program provides you with the resources you need to efficiently identify high-risk patients, educate them on the value of genetic testing, and administer these potentially life-saving tests.

What tools are included in the Myriad Breast Cancer Risk Assessment Program? 

MyGeneHistory®
Online screening tool that clearly identifies patients who meet national guidelines for hereditary cancer testing

Pre-Test Patient Education
Educational videos, printed education, and on-demand calls with a Genetic Counselor

Post-Test Patient Education
Patient test results education resources, including consultation with a Genetic Counselor

Clinical Support Team
Dedicated clinical support from Myriad Genetic Counselors (GCs) and Medical Science Liaisons (MSLs)

9 out of 10 providers

said the patient education video and speaking to a Genetic Counselor improved patients’ understanding of genetic testing1

said the patient education video and speaking to a Genetic Counselor improved patients’ understanding of genetic testing1

7out of 10
providers

were able to easily incorporate the video content and other resources into their daily practice1

Integrates seamlessly into your clinical workflows

The Myriad Breast Cancer Risk Assessment Program makes every phase of hereditary breast cancer risk management simpler and more streamlined, including:

  • Identifying guideline-eligible patients 
  • Evaluating hereditary cancer risk using the MyRisk® Test with RiskScore® 
  • Accurately diagnosing hereditary cancer syndromes 
  • Recommending appropriate steps to help manage patients’ risk

You don’t need any specialized genetics expertise to utilize these tools with your patients. And if you do need assistance, Myriad’s board-certified Genetic Counselors and MSLs are available to help you and your patients at any point in the process.  

Early knowledge is power

By offering hereditary cancer risk assessment services, you can identify high-risk patients sooner and ensure you’re delivering the standard of care, in compliance with societal best practices.2,4,5,*  

*ACOG, NPWH & USPSTF

Schedule a consultation to learn more about the program

Fill out the form below to get started.

Get started with Myriad's MyRisk Hereditary Cancer Test

Request more information about how Myriad’s MyRisk Hereditary Cancer Test can benefit your patients.



By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











  1. Waldman, Richard N. MD; DeFrancesco, Mark S. MD; Feltz, John P. MD; Welling, Daniel S. MD; Neiman, Wade A. MD; Pearlstone, Melissa M. MD; Marraccini, Christine A. MD; Karanik, Dana RN; Mielcarski, Elaine CNM; Schneider, Logan MS; Lenz, Lauren MS; Smith, Edith C. DNP; Taber, Katherine Johansen PhD; Adkins, Royce T. MD, FACS. Online Screening and Virtual Patient Education for Hereditary Cancer Risk Assessment and Testing. Obstetrics & Gynecology 145(2):p 177-185, February 2025 
  2. Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793. Obstetrics & Gynecology 134(6):p 1366-1367, December 2019. | DOI: 10.1097/AOG.0000000000003563
  3. DeFrancesco, et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstetrics and Gynecology 2018.
  4. National Association of Nurse Practitioners in Women’s Health. Position Statement: Hereditary breast and Ovarian Cancer Risk Assessment, April 2017. www.npwh.org
  5. US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA 2019;322:652–65